Close Menu

Biocartis

The assay runs on the company's fully automated PCR-based Idylla platform and detects various strains of the flu virus and respiratory syncytial virus.

The company will use the money to develop liquid biopsy versions of its solid tumor BRAF and KRAS diagnostics as part of a larger research collaboration.

The company's revenues rose nearly 500 percent year over year, driven by collaboration revenues received from Janssen Pharmaceutica.

The test detects 21 relevant mutations in the KRAS oncogene including mutations in exons 2, 3, and 4. 

The Belgian MDx firm's sights are set on assays for cancer, infectious disease, and sepsis, as well as new iterations of its flagship Idylla platform. 

The companies' first offering is expected to be a multiplex respiratory disease panel.

Three new assays were presented in posters at April's Clinical Virology Symposium.

The company issued more than 8.6 million shares at €11.50 per share in its IPO. Its shares list on Euronext Brussels under ticker symbol "BCART."

The partners will collaborate on a multiplex, real-time PCR-based assay for use with Biocartis' pre-enrichment platform, currently under development. 

Biocartis will initially test the device against synthetic virus samples and subsequently run trials in West Africa.

Pages

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.